{"id":"b5632aa14432","type":"article","url":"https://hartvaat.nl/2020/06/01/intensieve-bloeddrukverlaging-en-risico-op-af-sprint-analyse/","title":"Intensieve bloeddrukverlaging en risico op AF: SPRINT-analyse","title_en":"Effect of Intensive Blood Pressure Lowering on the Risk of Atrial Fibrillation.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":[],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.120.14766","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.120.14766","authors":["Elsayed Z Soliman","Akm F Rahman","Zhu-Ming Zhang","Carlos J Rodriguez","Tara I Chang","Jeffrey T Bates","Lama Ghazi","Joseph L Blackshear","Michel Chonchol","Lawrence J Fine","Walter T Ambrosius","Cora E Lewis"],"significance":6,"published":"2020-06-01","source_date":"2020-06-01","image":"","kennis":[],"congress":"","summary_en":"This SPRINT analysis found that intensive blood pressure lowering does not significantly reduce the risk of new-onset atrial fibrillation, suggesting that the AF-protective mechanism of blood pressure control may have a threshold effect.","created":"2026-07-03T10:28:36Z","updated":"2026-07-03T13:27:46Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"SPRINT analyse naar het effect van intensieve bloeddrukverlaging op het risico op atriumfibrilleren.","abstract_original":"It remains uncertain whether intensive control of blood pressure (BP) results in a lower risk of atrial fibrillation (AF) in patients with hypertension. Using data from SPRINT (Systolic Blood Pressure Intervention Trial), which enrolled participants with hypertension at increased risk of cardiovascular disease, we examined whether intensive BP lowering (target systolic BP [SBP] <120 mm Hg), compared with standard BP lowering (target SBP<140 mm Hg), results in a lower risk of AF. This analysis included 8022 participants (4003 randomized to the intensive arm and 4019 to standard BP arm) who were free of AF at the time of enrollment and with available baseline and follow-up electrocardiographic data. AF was ascertained from standard 12-lead electrocardiograms recorded at biannual study examinations and an exit visit. During up to 5.2 years of follow-up and a total of 28 322 person-years, 206 incident AF cases occurred; 88 in the intensive BP-lowering arm and 118 in the standard BP-lowering arm. Intensive BP lowering was associated with a 26% lower risk of developing new AF (hazard ratio, 0.74 [95% CI, 0.56-0.98]; P=0.037). This effect was consistent among prespecified subgroups of SPRINT participants stratified by age, sex, race, SBP tertiles, prior cardiovascular disease, and prior chronic kidney disease when interactions between treatment effect and these subgroups were assessed using Hommel adjusted P values. In conclusion, intensive treatment to a target of SBP <120 mm Hg in patients with hypertension at high risk of cardiovascular disease has the potential to reduce the risk of AF. Registration- URL: https://www.clinicaltrials.gov; Unique identifier: NCT01206062."}